



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



PT2385

Item No. 21325

CAS Registry No.: 1672665-49-4
Formal Name: 3-[[[(1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-fluoro-benzonitrile
MF: C₁₇H₁₂F₃NO₄S
FW: 383.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PT2385 is supplied as a solid. A stock solution may be made by dissolving the PT2385 in the solvent of choice, which should be purged with an inert gas. PT2385 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

PT2385 is an inhibitor of hypoxia-inducible factor-2 α (HIF-2 α ; IC₅₀ = 12 nM).¹ It inhibits HIF-2 α -induced transcription of intratumoral *Vegfa* mRNA and reduces tumor volume in a 786-O renal cell carcinoma mouse xenograft model when administered at a dose of 10 mg/kg. PT2385 (20 mg/kg) also inhibits the production of soluble FMS-related tyrosine kinase 1 (sFlt1) and prevents the development of hypertension and proteinuria, markers of preeclampsia, in pregnant rat dams.²

References

1. Wehn, P.M., Rizzi, J.P., Dixon, D.D., *et al.* Design and activity of specific hypoxia-inducible factor-2 α (HIF-2 α) inhibitors for the treatment of clear cell renal cell carcinoma: Discovery of clinical candidate s-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). *J. Med. Chem.* **61(21)**, 9691-9721 (2018).
2. Colson, A., Depoix, C.L., Lambert, I., *et al.* Specific HIF-2 α (hypoxia-inducible factor-2) inhibitor PT2385 mitigates placental dysfunction in vitro and in a rat model of preeclampsia (RUPP). *Hypertension* **80(5)**, 1011-1023 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/24/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM